Figure 1

![Figure 1: Overview of curcumin's molecular targets in neurological diseases, including modulation of inflammatory pathways and amyloid-beta aggregation. Despite promising in vitro data, bioavailability remains a key challenge for clinical translation.]()

> Source: Stella Gagliardi et al. "Curcumin Formulations and Trials: What's New in Neurological Diseases.." *Molecules (Basel, Switzerland)*, 2020. PMID: [33217959](https://pubmed.ncbi.nlm.nih.gov/33217959/)

<figure>
  <img src="" alt="Overview of curcumin's molecular targets in neurological diseases, including modulation of inflammatory pathways and amyloid-beta aggregation. Despite promising in vitro data, bioavailability remains a key challenge for clinical translation." />
  <figcaption>Figure 1. Overview of curcumin's molecular targets in neurological diseases, including modulation of inflammatory pathways and amyloid-beta aggregation. Despite promising in vitro data, bioavailability remains a key challenge for clinical translation.<br>  Source: Stella Gagliardi et al. "Curcumin Formulations and Trials: What's New in Neurological Diseases.." <em>Molecules (Basel, Switzerland)</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33217959/">33217959</a></figcaption>
</figure>